High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma

Bone Marrow Transplantation

Volumn 20, Issue 10, 1997, Pages 843-846

  Atra, A ^a   Whelan, J S ^b   Calvagna, V ^a   Shankar, A G ^a   Ashley, S ^a   Shepherd, V ^a   Souhami, R L ^b   Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Autologous stem cell rescue; Busulphan melphalan; High risk Ewing's sarcoma

Indexed keywords

BUSULFAN; CHLORMETHINE DERIVATIVE; MELPHALAN; SULFONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONVULSION; CYTOMEGALOVIRUS INFECTION; EWING SARCOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER VENOOCCLUSIVE DISEASE; MALE; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS PNEUMONIA;

EID: 0030859661     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700992     Document Type: Article

References (24)

1. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61: 23-32.
2. Nesbit ME, Gehan EA, Burgest EO et al. Multimodal therapy for the management of primary, non-metastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 1990; 8: 1664-1674.
3. Evans RG, Nesbit ME, Gehan EA et al. Multimodal therapy for the management of localised Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol 1991; 9: 1173-1 180.
4. Sandoval C, Meyer WH, Parham DM et al. Outcome in 43 children presenting with metastatic Ewing's sarcoma: the St Jude Children's Research Hospital Experience, 1962 to 1992. Med Ped Oncol 1996; 26: 80-185.
5. Craft A.W, Cotterill S, Imeson J on behalf of the United Kingdom Children's Cancer Study Group and the Bone Sarcoma Working Party of the Medical Research Council. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. Am J Pediatr Hematol Oncol 1993; 15 (Suppl. A): S31-S35.
6. Peters WP, Eder JP, Henner WD et al. High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 1986; 4: 646-654.
7. Hartmann O, Benhamou E, Beaujean F et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986; 4: 1804-1810.
8. Phillips GL, Shepherd JD, Barnett MJ et al. Busulfan, cyclophosphamide and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 1991; 9: 1880-1888.
9. Maraninchi D, Pico JL, Hartmann O et al. High-dose melphalan with or without marrow transplantation: a study of dose effect in patients with refractory and/or relapsed acute leukaemias. Cancer Treat Rep 1986; 70: 445-448.
10. Cornbleet MA, Corringham RET, Prentice HG et al. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1981 ; 56: 241-244.
11. Hartmann O, Vassal G, Valteau D et al. Autologous bone marrow transplantation in paediatric solid tumours: phase II studies. Bone Marrow Transplant 1991; 7: 106-111.
12. Bagnulo S, Perez DJ, Barrett A et al. High dose melphalan and autologous bone marrow transplantation for solid tumours in childhood. Eur J Paed Haematol Oncol 1985; 1: 129-133.
13. Burdach S, Jurgen H, Peters C et al. Myeloablative radio-chemotherapy and hemopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-1488.
14. Cony-Makhoul P, Marit G, Boiron JM et al. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Bone Marrow Transplant 1995; 16: 69-70.
15. Phillips MB, Pinkerton CR. High-dose busulphan/melphalan in pediatric malignancy (meeting abstract). Med Pediatr Oncol 1991; 19: 399-400.
16. Srivastava A, Bradstock KF, Szer J et al. Busulphan and melphalan prior to autologous bone transplantation. Bone Marrow Transplant 1993; 12: 323-329.
17. Skinner R, Sharkey IM, Pearson ADJ et al. Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 1993; 11: 173-190.
18. Kinsella TJ, Glaubiger D, Diesseroth A et al. Intensive combined modality therapy including low-dose TBI in high risk Ewing's sarcoma patients. Int J Radiat Oncol Biol Phys 1983; 9: 1955-1960.
19. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697-705.
20. Stewart DA, Gyonyor E, Paterson AHG et al High-dose melphalan ± total body irradiation and autologus hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant 1996; 18: 315-318.
21. Hassan M, Oberg G, Bjorkhom M at al. Influence of prophylactic anticonvulsant therapy on high dose busulphan kinetics. Cancer Chem Pharm 1992; 33: 181-186.
22. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chem Pharm 1991; 28: 130-134.
23. Yeager AM, Wager JE, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
24. Grochow LB, Krivit W, Whitley CB et al. Busulfan disposition in children. Blood 1990; 75: 1723-1727.